Questionnaire for the identification of non-adherence barriers in patients receiving intravitreal injection

Our Analyses showed that the majority of these patients face a substantial amount of adherence barriers, especially with regards to the time commitment to receive the treatment, associated travel/opportunity costs, as well as depressive moods. Nonetheless, by understanding the diverse challenges faced by their patients, physicians have the opportunity to address barriers either directly or

Lees meer

We have set a high standard

Last week the CieBOM in the Netherlands proposed new criteria for clinical relevance in oncology therapies studied in non-randomized clinical trials. An increasing number of treatments achieve EMA registration based on non-randomized trials, especially in rare indications. CieBOM currently does not evaluate these therapies as it only decides on therapies that were studied in an

Lees meer

New Publication!

We are happy to present our latest scientific contribution! Our colleagues Andrea Garcia and Bart Heeg collaborated with our partners to estimate the health impact of tafamidis in cardiomyopathy. The publication presents a disease simulation model in Transthyretin amyloid cardiomyopathy, a rare disease with a typically poor prognosis. The model aimed to estimate the impact

Lees meer

HEOR & RWE Solution Center

We are proud to announce that Cytel is an HEOR Solutions Center partner! Explore our profile, connect with our experts in HEOR and RWE, access top publications and more today! https://lnkd.in/eCNb4N8

Lees meer

New Publication!

We are happy to share our new collaboration! In this new publication in Current Medical Research and Opinion, Bart Heeg collaborated to indirectly compare the efficacy of bosutinib with nilotinib and dasatinib in first-line chronic-phase chronic myeloid leukemia. Because heterogeneity in terms of patient baseline characteristics and imatinib dose escalation are difficult to adjust for in network

Lees meer

Manuscript on unmet needs in IBD patients not treated with biologics published

In our recent publication, the Ingress-Health RWE team, together with clinical experts, analyzed a big German claims dataset with >8 million insured to explore unmet needs in patients with Inflammatory Bowel disease not treated with biologics. The team identified a substantial percentage of patients who suffer from active disease and/or steroid dependency, and the majority

Lees meer

Urinary tract infections cost in type 2 DM patients, data from 456,586 German patients

INGRESS published a paper about cost of urinary tract infections in type 2 diabetes patients; 456,586 T2DM-patients were included from a regional German healthcare fund database. We calculated UTI-associated resource costs. We observed 48,337 UTI events. The direct mean resource-based costs were €315.90 per UTI event. Healthcare costs per patient year were €3,916 higher in

Lees meer

First DCE analysis in age-related wet macular degeneration!

The Ingress-health team recently published the very first discrete-choice based preference analysis in patients with age-related wet macula degeneration. This technique had not been used so far in this disease, so this is the first worldwide publication in this respect. It is published in the high-impact ophthalmology journal “Ophthalmology”. The results of the analysis show

Lees meer

Non-persistence/non-adherence in T2DM patients; insights from UK and Germany real-world setting

In our recently published work, we have utilized data from two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010–2012). The study included 1,905 and 1,627 type 2 diabetes mellitus (T2DM) patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists from the UK and Germany, respectively.

Lees meer

What risk factors are associated with UTI in T2DM patients?

Insights from a real-world setting, 456,586 T2DM German patients. In our recently published work we investigated urinary tract infection (UTI) incidence among Type 2 Diabetes mellitus (T2DM) patients in Germany. Moreover, we aimed to identify risk factors associated with UTI incidence/recurrence. A total of 456,586 T2DM- patients were identified. Overall, the UTI event rate was

Lees meer